Compare Travere Therapeutics Inc. Common Stock (TVTX) vs Workiva Inc (WK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Travere Therapeutics Inc. Common Stock vs Workiva Inc — how do they compare? Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B), while Workiva Inc trades at $72.22 (market cap $3.95B). The key difference: Travere Therapeutics Inc. Common Stock is the larger of the two by market cap, and Workiva Inc is more actively traded (612,757 versus 1,668,577). Which is the better fit depends on your goals — on Pluang, investors hold Travere Therapeutics Inc. Common Stock for 0 Days and Workiva Inc for 20 Days on average.
| TVTX | WK | |
|---|---|---|
Market Cap | $4.88B | $3.95B |
Volume | 1,668,577 | 612,757 |
Sector | Health | Technology |
52-Week High | $67.52 | $93.31 |
52-Week Low | $26.79 | $44.31 |
Typical Hold Time | 0 Days | 20 Days |
Enterprise Value | $5.01B | $3.92B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
WK trades at $72.50, down 0.74% on the day, with strong technical momentum showing bullish moving averages and support at $72. The company demonstrates robust revenue growth, reaching $966M in 2026 with net income turning positive at $47M, while consistently beating earnings expectations. Recent product innovations in AI and regulatory technology highlight ongoing business development.
The outlook remains positive with 89% analyst buy ratings and an $86 price target, though elevated valuation multiples and execution risks in competitive markets warrant caution. Upside potential exists if earnings growth continues, but investors should monitor margin sustainability and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →About Workiva Inc
Workiva is a leading provider of cloud-based platforms for complex reporting and compliance. It enables organizations to connect and manage data across financial reporting, ESG (Environmental, Social, and Governance), and GRC (Governance, Risk, and Compliance), serving as a single source of truth for auditable, transparent disclosures to regulators and stakeholders.
Read more on WK →
